Vicore Pharma Holding AB (publ) (STO: VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
8.88
+0.19 (2.19%)
Jan 20, 2025, 3:49 PM CET
-33.88%
Market Cap 2.04B
Revenue (ttm) 104.24M
Net Income (ttm) -196.45M
Shares Out 234.58M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,558
Average Volume 737,144
Open 8.75
Previous Close 8.69
Day's Range 8.74 - 8.99
52-Week Range 6.92 - 24.10
Beta 0.64
RSI 49.26
Earnings Date Feb 27, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.